Chronic Kidney Disease Market Size, Share, and Industry Analysis, By Drug Class (ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta-blockers, Erythropoiesis-stimulating Agents (ESAs), Diuretics, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

The global chronic kidney disease market is witnessing significant growth due to the increasing incidence of the disease across the globe. Chronic kidney disease (CKD) is a progressive condition characterized by a gradual loss of kidney function over months to years. The main risk factors for developing kidney disease are diabetes, high blood pressure, heart disease, and a family history of kidney failure.

• For instance, according to data published by The Professional Society for Health Economics and Outcomes Research (ISPOR) in 2023, in the U.K., an estimated 3.25 million adults are suffering from chronic kidney disease.

The market growth is further driven by the increasing prevalence of diabetes and high blood pressure, and increasing diagnostics rates across the globe. Additionally, growing number of drug candidates in the pipeline is expected to increase the product launches and the demand for treatment is anticipated to grow over the forecast period.

Chronic Kidney Disease Market Driver

Increasing Prevalence of Chronic Kidney Diseases to Boost Market

The market expansion is primarily driven by the increasing prevalence of CKD across the globe. Key factors contributing to this CKD are the rising incidence of diabetes-related nephropathy and hypertension-induced renal diseases.

• As per a CDC report in May 2024, about 14% of adults in the U.S., translating to roughly 35.5 million individuals, have CKD. This is expected to drive the demand for effective drugs.

The market is also bolstered by an aging population and increased awareness regarding early diagnosis and management of kidney diseases.

Request a Free sample to learn more about this report.

Chronic kidney disease is a progressive condition that affects >10% of the general population worldwide, amounting to more than 800 million individuals. The disease is more prevalent in older individuals, women, racial minorities, and in people experiencing diabetes mellitus and hypertension.

Chronic Kidney Disease Market Restraint

Factors Restricting Patient Adherence May Limit Market Growth

Patient adherence to medication is crucial for managing the chronic kidney disease (CKD), yet various factors can significantly restrict the adherence, ultimately limiting the growth of the global market. As CKD is associated with various chronic diseases, managing a high number of drugs in individuals limits patient adherence.

• Additionally, the high cost associated with low-income countries further limits the patient adherence. Furthermore, common side effects of some drugs, such as hyperkalemia or elevated potassium levels from ACE inhibitors, can limit the adoption and market growth.

Chronic Kidney Disease Market Opportunity

Novel Pipeline Candidates to Boost Market Growth in the Future

The chronic kidney disease (CKD) market presents significant opportunities, particularly with the emergence of novel therapeutics aimed at improving patient outcomes. As the global prevalence of CKD continues to rise, driven by factors such as aging populations and increasing rates of diabetes and hypertension, the demand for innovative treatment options is becoming more pronounced.

• For instance, recent advancements in therapies such as the SGLT2 inhibitors and GLP-1 receptor agonists have shown promise in managing diabetes and slowing the progression of kidney disease. Moreover, the pipeline and R&D initiatives are expected to offer new opportunities in the market.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Chronic Kidney Disease, By Key Countries, 2023


• New Product Launches/ Approvals, By Key Players


• Pipeline Analysis, By Key Players


• Key Industry Developments (Mergers, Acquisitions, Partnerships)


• Impact of COVID-19 on the Market

Analysis by Drug Class

Based on drug class, the chronic kidney disease market is divided into ACE inhibitors, angiotensin-ii receptor blockers, calcium channel blockers, beta-blockers, erythropoiesis-stimulating agents (ESAs), diuretics, and others.

The ACE inhibitors segment accounted for a significant revenue in the market. This class is widely used as a first-line treatment for CKD, particularly in patients with hypertension and diabetic nephropathy. They work by reducing blood pressure and proteinuria, which helps slow kidney damage progression.

• For instance, a report published in Drugs in April 2020 stated that ACE inhibitors can prevent end-stage renal disease by treating the underlying cause and this being the first line option is expected to boost the segmental growth.

Analysis by Route of Administration

Based on the route of administration, the chronic kidney disease market is divided into oral and parenteral.

The oral segment held a significant share of the market. The preference for oral medications is driven by their convenience and the increasing demand for self-administration options among patients. Additionally, new product launches are boosting the segment growth.

• For instance, in March 2022, Zydus Lifesciences received approval from the Drug Controller General of India for Oxemia, an oral medication designed to manage anemia associated with CKD. Such effective product launches are expected to boost the segmental growth.

Analysis by Distribution Channel

Based on distribution channel, the market is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The hospital pharmacies accounted for a significant share in the market. Convenience to the patients and easy availability of the drugs at hospital pharmacies are the factors driving the growth of this segment. Growing number of CKD cases globally and their diagnosis at hospitals are the factors responsible for the growth of the segment.

• For instance, an article published in Nature Reviews Nephrology in April 2024 stated that the global prevalence of CKD increased by 33% between 1990 and 2017, indicating a significant rise in cases requiring hospitalization and the demand for drugs in hospital pharmacies.

Regional Analysis

To gain extensive insights into the market, Request for Customization

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America is projected to lead the global market for chronic kidney diseases throughout the forecast period. This dominance can be attributed to several key factors, including a high prevalence of CKD and the presence of major companies in the region.

• According to 2023 statistics published by the CDC, more than 1 in 7 adults in the U.S. (nearly 35.5 million people) are estimated to have chronic kidney diseases (CKD).

Additionally, the region benefits from a strong adoption rate of advanced drugs and increased awareness about diagnosis, which collectively are expected to drive market growth.

Europe is anticipated to hold the second-largest share of the market. This is largely due to a growing demand for innovative therapies and improved patient outcomes.

The Asia Pacific region is experiencing rapid growth in the CKD market, driven by rising awareness and increasing incidence rates. As per an article published in the Journal Drugs in April 2020, China and India has an estimated 159.8 million and 140.2 million adults affected by CKD respectively.

The Latin America and the Middle East & Africa (MEA) markets currently represent a moderate share of the market. However, the improvements in awareness and increased healthcare spending in these regions are anticipated to stimulate growth over the coming years.

Key Players Covered

The global chronic kidney disease market is partially consolidated with few key players.

The report includes the profiles of the following key players:

• GlaxoSmithKline plc. (U.K.)


• Sanofi (France)


• AstraZeneca (U.K.)


• Amgen Inc (U.S.)


• Kissei Pharmaceutical Co., Ltd (Japan)


• Johnson & Johnson Services, Inc (U.S.)


• Hoffmann-La Roche AG (Switzerland)


• Sanofi (France)


• Teva Pharmaceutical Industries Ltd. (Israel)

Key Industry Developments

• In September 2023, Boehringer Ingelheim International GmbH received the U.S. Food and Drug Administration (FDA) approval for Jardiance (empagliflozin) 10 mg tablets in adults with chronic kidney disease (CKD).


• In September 2019, Johnson & Johnson Services, Inc., received the U.S. FDA approval for their drug INVOKANA (canagliflozin), for the treatment of chronic kidney disease for patients with Type II diabetes.